Home Cart 0 Sign in  

[ CAS No. 4781-83-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 4781-83-3
Chemical Structure| 4781-83-3
Structure of 4781-83-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 4781-83-3 ]

Related Doc. of [ 4781-83-3 ]

Alternatived Products of [ 4781-83-3 ]

Product Details of [ 4781-83-3 ]

CAS No. :4781-83-3 MDL No. :MFCD00039013
Formula : C4H8ClNS Boiling Point : -
Linear Structure Formula :- InChI Key :ATGUDZODTABURZ-UHFFFAOYSA-N
M.W : 137.63 Pubchem ID :13166855
Synonyms :
2-Iminothiolane hydrochloride
Chemical Name :2-Iminothiolane hydrochloride

Calculated chemistry of [ 4781-83-3 ]

Physicochemical Properties

Num. heavy atoms : 7
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.75
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 37.37
TPSA : 49.15 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.0 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 1.61
Log Po/w (WLOGP) : 2.29
Log Po/w (MLOGP) : 0.62
Log Po/w (SILICOS-IT) : 2.12
Consensus Log Po/w : 1.33

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.71
Solubility : 2.7 mg/ml ; 0.0196 mol/l
Class : Very soluble
Log S (Ali) : -2.25
Solubility : 0.767 mg/ml ; 0.00557 mol/l
Class : Soluble
Log S (SILICOS-IT) : -1.06
Solubility : 12.1 mg/ml ; 0.0879 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.77

Safety of [ 4781-83-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P302+P352-P304+P341-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 4781-83-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 4781-83-3 ]

[ 4781-83-3 ] Synthesis Path-Downstream   1~55

  • 1
  • [ 4781-83-3 ]
  • [ 70024-90-7 ]
  • thiolated human serum albumin [ No CAS ]
  • 2
  • [ 4781-83-3 ]
  • subtilisin Carlsberg [ No CAS ]
  • subtilisin Carlsberg, modified in N-terminal with 2-iminothiolane hydrochloride [ No CAS ]
  • 3
  • [ 7284-37-9 ]
  • [ 1631-26-1 ]
  • [ 4781-83-3 ]
  • 4-(1-Benzyl-2,5-dioxo-pyrrolidin-3-ylsulfanyl)-N-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-butyramidine; hydrochloride [ No CAS ]
  • 4
  • [ 6318-23-6 ]
  • [ 1631-26-1 ]
  • [ 4781-83-3 ]
  • 4-(1-Benzyl-2,5-dioxo-pyrrolidin-3-ylsulfanyl)-N-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-butyramidine; hydrochloride [ No CAS ]
  • 5
  • [ 4781-83-3 ]
  • Me-(OCH2CH2)m-NH-[(L)-CO-CH(CH2CH2CH2CH2NH2)-NH]n-H [ No CAS ]
  • Me-(OCH2CH2)m-NH-[(L)-CO-CH(CH2CH2CH2CH2CH2-NH2)-NH]n-H, ω-amino-groups partially acylated with 4-thioiminobutyric acid [ No CAS ]
  • 6
  • 23-demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)aminotilmicosin [ No CAS ]
  • [ 4781-83-3 ]
  • C45H81N5O8S*ClH [ No CAS ]
  • 7
  • (Sa)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-D-lyxo-hexopyranosyl)-D-glucopyranosyl]oxy}-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-[(2R)-4-methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo-22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9] oxadiazacyclohexadecino[4,5-m][10,2,16]-benzoxadiazacyclotetracosine-26-carboxylic acid monohydrochloride [ No CAS ]
  • [ 4781-83-3 ]
  • C70H82Cl2N10O24S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In water; at 20℃; for 2h; Vancomycin hydrochloride 17 (10 mmol) is) is dissolved in water (100 mL), stirred at room temperature, and treated sequentially with triethylamine (40 mmol) and <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (10 mmol). After two hours the reaction mixture is fractionated by reverse-phase HPLC using a linear gradient of acetonitrile in water (both buffered with 0. 1% trifluoracetic acid) to afford the imine adducts modified on the N-methylamino terminus compound 26 and on the N'-amino group of the vancosamine residue compound 27.
  • 8
  • chitosan, molecular mass 400 kDa [ No CAS ]
  • [ 4781-83-3 ]
  • chitosan-iminothiolane conjugate [ No CAS ]
  • 9
  • chitosan, MM = 400 kDa [ No CAS ]
  • [ 4781-83-3 ]
  • chitosan-4-thiobutylamidine conjugate [ No CAS ]
  • 10
  • [ 4781-83-3 ]
  • [ 9012-76-4 ]
  • chitosan-4-thiobutylamidine conjugate [ No CAS ]
  • 11
  • 5-(2-aminoethylsulfonyl)pentyl (α-L-idopyranosyluronate)-(1->4)-(2-amino-2-deoxy-α-D-glucopyranoside)-(1->4)-(β-D-glucopyranosyluronate)-(1->4)-N-acetyl-2-amino-2-deoxy-α-D-glucopyranoside [ No CAS ]
  • [ 4781-83-3 ]
  • C37H64N4O24S2 [ No CAS ]
  • 12
  • [ 2127-03-9 ]
  • [ 4781-83-3 ]
  • [ 123628-75-1 ]
  • [ 300711-57-3 ]
  • 13
  • chitosan, medium molecular mass: 400 kDa [ No CAS ]
  • [ 4781-83-3 ]
  • chitosan-4-thiobutylamidine conjugate, content of thiol groups: 304.9 μmol/g, fraction of oxidized thiol groups: 6.5% [ No CAS ]
  • 14
  • [ 4781-83-3 ]
  • poly-L-lysine [ No CAS ]
  • PLL(SH)n [ No CAS ]
YieldReaction ConditionsOperation in experiment
In water; at 20℃; for 0.75h;Aqueous borate buffer; Derivatized poly-1-lysine was generated using the thiolating agent, 2-iminothiolane to thiolate the free amino group present on the lysine residues of a poly-1-lysine (PLL) polymer backbone. To generate this reagent 94 mg of poly-1-lysine (MW=14600) was diluted in 10 ml of a 50 mM sodium borate buffer. Subsequently 2-iminothiolane was diluted 10 mg/ml in borate buffer and added to 5 ml of the PLL at the following ratios:;The thiolation reaction was carried out at room temperature for 45 minutes. The thiolated poly-lysine agent (PLL(SH)n was dialyzed against borate buffer for 4 hours with two buffer changes every two hours.
  • 15
  • [ 4781-83-3 ]
  • [ 123-30-8 ]
  • [ 62850-53-7 ]
YieldReaction ConditionsOperation in experiment
With potassium hydroxide; In ethanol; EXAMPLE 12 Preparation of 2(4-Hydroxyphenyl)imino-1,3-dithiolane A mixture of p-aminophenol (81.8 g, 0.75 mol), <strong>[4781-83-3]iminothiolane hydrochloride</strong> (116.7 g, 0.75 mol) and ethanol (1500 ml) is stirred and heated at reflux overnight. Charcoal and hyflo are then added to the reaction mixture and it is filtered hot. The filtrate is cooled overnight, the crystallized product filtered off yielding 34.5 g, as a tan solid. Additional product is obtained by washing the filter cake from the above hot filtration with 10% potassium hydroxide solution (600 ml). The solution is neutralized with concentrated hydrochloric acid and the precipitated product filtered. The combined yield is 95.8 g (60% of theory) of a tan solid, melting point 204 C to 208 C.
  • 16
  • [ 4781-83-3 ]
  • [ 78619-84-8 ]
  • [ 1470026-61-9 ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In water; at 20℃; for 2h; 4,4'-Dipiperidine hydrochloride (10 mmol) is dissolved in water (100 mL), stirred at room temperature, and treated sequentially with triethylamine (40 mmol) and <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (20 mmol). After two hours the reaction mixture is frozen and lyopholized and the diamidine dithiol 8 is recovered as the dihydrochloride after crystallization from HCl/diethyl ether.
  • 17
  • (Sa)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-D-lyxo-hexopyranosyl)-D-glucopyranosyl]oxy}-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-[(2R)-4-methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo-22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9] oxadiazacyclohexadecino[4,5-m][10,2,16]-benzoxadiazacyclotetracosine-26-carboxylic acid monohydrochloride [ No CAS ]
  • [ 4781-83-3 ]
  • C70H82Cl2N10O24S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In water; at 20℃; for 2h; Vancomycin hydrochloride 17 (10 mmol) is) is dissolved in water (100 mL), stirred at room temperature, and treated sequentially with triethylamine (40 mmol) and <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (10 mmol). After two hours the reaction mixture is fractionated by reverse-phase HPLC using a linear gradient of acetonitrile in water (both buffered with 0. 1% trifluoracetic acid) to afford the imine adducts modified on the N-methylamino terminus compound 26 and on the N'-amino group of the vancosamine residue compound 27.
  • 18
  • C68H81Cl2N11O23 [ No CAS ]
  • [ 4781-83-3 ]
  • C72H88Cl2N12O23S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In water; at 20℃; for 2h; Compound 31 (5.0 mmol) is) is dissolved in water (50 mL), stirred at room temperature, and treated sequentially with triethylamine (20 mmol) and <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (5.0 mmol). After two hours the reaction mixture is fractionated by reverse-phase HPLC using a linear gradient of acetonitrile in water (both buffered with 0. 1% trifluoracetic acid) to afford compound 32 after lyopholization of the appropriate fractions.
  • 19
  • [ 4781-83-3 ]
  • recombinant human serum albumin [ No CAS ]
  • nitroso-modified recombinant human serum albumin with 2-iminothiolane as spacer, NO/HSA = 6.64 mol/mol [ No CAS ]
  • 20
  • [ 128-53-0 ]
  • C10H25N4Pol [ No CAS ]
  • [ 4781-83-3 ]
  • [ 1109218-28-1 ]
  • 21
  • C10H25N4Pol [ No CAS ]
  • [ 1109218-14-5 ]
  • [ 4781-83-3 ]
  • C30H50N9O7PolS2*ClH [ No CAS ]
  • 22
  • C10H25N4Pol [ No CAS ]
  • C37H36N4O9 [ No CAS ]
  • [ 4781-83-3 ]
  • C30H51N9O7S [ No CAS ]
  • 23
  • C10H25N4Pol [ No CAS ]
  • [ 1109218-18-9 ]
  • [ 4781-83-3 ]
  • [ 1109218-39-4 ]
  • 24
  • C10H25N4Pol [ No CAS ]
  • [ 1109218-21-4 ]
  • [ 4781-83-3 ]
  • [ 1109218-41-8 ]
  • 25
  • [ 941-69-5 ]
  • C10H25N4Pol [ No CAS ]
  • [ 4781-83-3 ]
  • [ 1109218-30-5 ]
  • 26
  • [ 7423-55-4 ]
  • C10H25N4Pol [ No CAS ]
  • [ 4781-83-3 ]
  • C21H39N6O4PolS*ClH [ No CAS ]
  • 27
  • LMWP-PDP [ No CAS ]
  • [ 4781-83-3 ]
  • bovine serum albumin [ No CAS ]
  • low-molecular-weight protamine peptide-bovine serum albumin conjugate [ No CAS ]
  • 28
  • LMWP-PDP [ No CAS ]
  • [ 4781-83-3 ]
  • ovalbumin [ No CAS ]
  • low-molecular-weight protamine peptide-ovalbumin conjugate [ No CAS ]
  • 29
  • LMWP-PDP [ No CAS ]
  • [ 4781-83-3 ]
  • lysozyme [ No CAS ]
  • low-molecular-weight protamine peptide-lysozyme conjugate [ No CAS ]
  • 30
  • [ 7284-37-9 ]
  • [ 4781-83-3 ]
  • C9H17NO5S*ClH [ No CAS ]
  • 31
  • [ 4781-83-3 ]
  • [ 60984-63-6 ]
  • [ 1331749-35-9 ]
  • 32
  • [ 71-44-3 ]
  • [ 4781-83-3 ]
  • [ 2265-22-7 ]
  • [ 499984-16-6 ]
  • [ 1150635-65-6 ]
  • 33
  • [ 4781-83-3 ]
  • [ 2265-22-7 ]
  • [ 155773-72-1 ]
  • C48H82FN11O8S [ No CAS ]
  • 34
  • 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] ammonium salt [ No CAS ]
  • [ 4781-83-3 ]
  • C136H270N3O54PS*ClH*H3N [ No CAS ]
  • 35
  • [ 4781-83-3 ]
  • (4-amino-1-hydroxybutylidene)bisphosphonic acid disodium salt [ No CAS ]
  • [ 1363155-66-1 ]
YieldReaction ConditionsOperation in experiment
In aq. phosphate buffer; for 1h;pH 7.5; The synthesis of Ale-SH was achieved by reacting alendronate with 2-IT (1 equivalent) in PBS at pH 7.5 for 1 hour followed by precipitation with EtOH. The solid was dissolved in water and precipitated with EtOH, twice.
  • 37
  • [ 23214-92-8 ]
  • [ 4781-83-3 ]
  • doxorubicin [ No CAS ]
YieldReaction ConditionsOperation in experiment
70% With triethylamine; In methanol; at 20℃; for 7h; Dox (50?mg, 0.09?mmol) and <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (12?mg, 0.09?mmol) were dissolved in methanol (40?mL) followed by addition of a catalytic amount of triethylamine (TEA) and stirred at rt for 7?h. After evaporation of the solution, the crude product was washed multiple times with diethyl ether affording 45?mg (70%) of Dox-SH. 1H NMR (DMSO-d6 + D2O, 400?MHz, delta ppm): 7.90-7.83 (m, 2H, ArC1H, ArC2H), 7.62-7.60 (m, 1H, ArC3H), 5.26 (t, J?=?12.0?Hz, 1H, H-1'), 4.95-4.86 (m, 1H, H-14), 4.50-4.59 (m, 3H, H-14 and H-7), 4.15 (d, J?=?8.0?Hz, 1H, H-5'), 3.95 (d, J?=?12.0?Hz, 3H, OCH3), 3.55-3.50 (m, 1H, H-4'), 3.39-3.30 (m, 1H, H-3'), 2.80-2.96 (m, 2H, H-10), 2.44-2.32 (m, 2H, CH2SH), 2.17-1.42 (m, 8H, CH2 (H-8), HSCH2CH2, CH2C=NH, CH2 (H-2'), 1.16-1.10 (br S, 3H, CH3); 13CNMR (DMSO-d6 + D2O, 100?MHz, delta ppm): 214.39 (C13?=?O), 187.07 (C12?=?O), 186.52 (C5=O), 166.53 (C-4), 161.33 (C=NH), 156.16 (C-6), 154..62 (C-11), 137.13 (C-6a), 135.40 (C-10a), 135.06 (C-12a), 134.51 (C-2), 120.33 (C-4a), 120.23 (C-1), 119.76 (C-3), 111.30 (C-5a), 110.93 (C-11a), 99.81 (C-1'), 75.73 (C-9), 75.37 (C-7), 70.35 (C-4'), 66.75 (C-5'), 64.25 (C-14), 57.16 (C4-OCH3), 47.06 (C3'), 36.77 (C-8), 32.57 (C-10), 32.46 (C-2'), 28.56 (CH2C(NH)?=?NH), 27.53 (CH2SH), 26.82 (CH2CH2SH), 17.21 (C-5'-CH3); HR-MS (ESI-qTOF) (m/z) [C31H36N2O11S]: calcd, 644.2040; found 645.4678 [M+H]+.
With triethylamine; In methanol; for 7h;pH 8.5; This compound was prepared using the same modified method in our previous work (under submission). Briefly, thiolated doxorubicin (Dox-SH) was prepared first by mixing Dox (40 mg, 0.07 mmol) and <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (10 mg, 0.07 mmol) in methanol (30 mL) followed by adding the catalytic amount of triethylamine (TEA) to achieve a pH of 8.5. After 7 h, the solution was evaporated, and the precipitate was crystalized by ether. HR-MS (ESI-qTOF) (m/z) [C31H36N2O11S]: calcd, 644.2040; found 645.2434 [M + H]+. The thiol group was activated by the reaction of Dox-SH (25 mg, 0.03 mmol) with 2,2'-dithiodipyridine (8 mg, 0.03 mmol) in methanol followed by adding a catalytic amount of acetic acid. After stirring overnight at room temperature, the solvent was evaporated, and the crude was purified by ether. HR-MS (ESI-qTOF) (m/z) [C36H39N3O11S2]: Calcd, 753.2026; Found 754.2511 [M + H]+.
  • 38
  • [ 119-04-0 ]
  • [ 4781-83-3 ]
  • C27H52N6O14S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With 5'-GGA CUG GGC GAG AAG UUU AGU CC-3'; In aq. phosphate buffer; at 20℃; for 24h; General procedure: 10110] This example demonstrates that the APG approach for regioselective transformation according to the present invention is compatible with diverse reagents in different reactions. Scheme 1 shows the chemo- and regioselective transformation of ring IV of neomycin as exemplary target compound 1. All reactions were performed in 10mM phosphate buffer at room temperature for 24 h in presence of 1 .5 equiv. ofAPGaptlThiolation: 5 equiv. of 9, pH 6.9
  • 39
  • [ 4781-83-3 ]
  • [ 4146-30-9 ]
  • C27H52N6O14S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With 5'-GGA CUG GGC GAG AAG UUU AGU CC-3'; In aq. phosphate buffer; at 20℃; for 24h; General procedure: 10114] A volume of 900 tL of a 5.54 mM RNA aptamer solution (4.98 tmol) in 10mM sodium phosphate buffer (pH 6.8) was heated to 85 C. for 10 mm and was afterwards kept at room temperature for 15 mm. 684 tL of a 4.8 mM solution of neomycin B sulphate (3.28 tmol) in 10mM sodium phosphate buffer (pH 7.4) was added and the mixture was allowed to stand for 30 mm at room temperature. Then, 15 equiv. activated ester, acetyl sulfo-NHS ester 4 or STP-ester 5 (49.2 tmol) 500 jiL 10mM sodium phosphate buffer (pH 7.4), or 5 equiv. <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (16.4 tmol) dissolved in 42 IL 10 mM sodium phosphate buffer (pH 7.4) were added and the reaction mixture was allowed to react for 24 hours at room temperature. Afier addition of 180 tL of a 7 wt.% ethylamine water solution and thrther incubation for 30mm at room temperature, 486 tl of a 2 M sodium hydroxidesolution were added and the crude mixture was heated to 90C. for 30 mm. After cooling to room temperature each 50 tLfraction was purified by HPLC using a Waters Spherisorb ODS-2C18 analytic colunm (water/acetone 1:0.81 containing 16.9mM HFBA) at a flow rate of 1 ml/min at 40 C. to afford the antibiotic derivatives 10 and 14. Afier evaporation of acetone and freeze-drying of collected fractions the product was taken up in 150 IL of D20 for NMR-studies.
  • 40
  • [ 71-44-3 ]
  • [ 2414-34-8 ]
  • [ 4781-83-3 ]
  • C36H59F2N5O4S [ No CAS ]
  • C62H92F4N6O8S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
In ethanol; at 40℃; for 1h; General procedure: BeS, Be2S, BuS, Bu2S, FS, and F2S were prepared using a reaction scheme previously described for the synthesis of DS and D2S (Gruneich et al., 2004). Briefly, the 21-mesylate form of each steroid was reacted separately into its mono- and di-substituted cationic products via a one-pot reaction involving molar excesses of both spermine and Traut?s reagent (<strong>[4781-83-3]2-iminothiolane HCl</strong>) in ethanol at 40C. Beclomethasone-21-mesylate and flumethasone-21-mesylate were synthesized as described earlier, and budesonide-21-mesylate was obtained from Steraloids (Newport, RI). Spermine and Traut?s reagent were obtained from Sigma-Aldrich. The reaction was allowed to proceed for ~1 hour before being quenched with trifluoroacetic acid (Sigma-Aldrich). Ethanol was removed through evaporation under vacuum, and the reaction products were dissolved in water before the purification process.
  • 41
  • [ 71-44-3 ]
  • [ 4781-83-3 ]
  • 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxapentacyclo[10.8.0.0<SUP>2</SUP>'<SUP>9</SUP>.0<SUP>4</SUP>'<SUP>8</SUP>.0<SUP>13</SUP>'<SUP>18</SUP>]icosa-14,17-dien-8-yl]-2-oxoethyl methanesulfonate [ No CAS ]
  • C39H65N5O5S [ No CAS ]
  • C68H104N6O10S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
In ethanol; at 40℃; for 1h; General procedure: BeS, Be2S, BuS, Bu2S, FS, and F2S were prepared using a reaction scheme previously described for the synthesis of DS and D2S (Gruneich et al., 2004). Briefly, the 21-mesylate form of each steroid was reacted separately into its mono- and di-substituted cationic products via a one-pot reaction involving molar excesses of both spermine and Traut?s reagent (<strong>[4781-83-3]2-iminothiolane HCl</strong>) in ethanol at 40C. Beclomethasone-21-mesylate and flumethasone-21-mesylate were synthesized as described earlier, and budesonide-21-mesylate was obtained from Steraloids (Newport, RI). Spermine and Traut?s reagent were obtained from Sigma-Aldrich. The reaction was allowed to proceed for ~1 hour before being quenched with trifluoroacetic acid (Sigma-Aldrich). Ethanol was removed through evaporation under vacuum, and the reaction products were dissolved in water before the purification process.
  • 42
  • [ 71-44-3 ]
  • beclomethasone-21-mesylate [ No CAS ]
  • [ 4781-83-3 ]
  • C36H60ClN5O4S [ No CAS ]
  • C62H94Cl2N6O8S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
In ethanol; at 40℃; for 1h; General procedure: BeS, Be2S, BuS, Bu2S, FS, and F2S were prepared using a reaction scheme previously described for the synthesis of DS and D2S (Gruneich et al., 2004). Briefly, the 21-mesylate form of each steroid was reacted separately into its mono- and di-substituted cationic products via a one-pot reaction involving molar excesses of both spermine and Traut?s reagent (<strong>[4781-83-3]2-iminothiolane HCl</strong>) in ethanol at 40C. Beclomethasone-21-mesylate and flumethasone-21-mesylate were synthesized as described earlier, and budesonide-21-mesylate was obtained from Steraloids (Newport, RI). Spermine and Traut?s reagent were obtained from Sigma-Aldrich. The reaction was allowed to proceed for ~1 hour before being quenched with trifluoroacetic acid (Sigma-Aldrich). Ethanol was removed through evaporation under vacuum, and the reaction products were dissolved in water before the purification process.
  • 43
  • [ 4781-83-3 ]
  • [ 25316-40-9 ]
  • C31H36N2O11S*ClH [ No CAS ]
  • 44
  • [ 124-22-1 ]
  • [ 4781-83-3 ]
  • N-dodecyl-4-mercaptobutanimidamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
55% With triethylamine; In methanol; acetonitrile; at 20℃; for 4h; In a round bottom flask 1.816 mmol dodecylamine (1 eqv), 1.816 mmol <strong>[4781-83-3]iminothiolane hydrochloride</strong> (1 eqv) and 1.998 mmol triethylamine (1.1 eqv) were dissolved in a mixture of 10 ml acetonitrile and 4 ml methanol. The solution was stirred at room temperature for approximately 4 h and the solvent was removed under reduced pressure. The crude product was purified via chromatography over silica as stationary phase and using diethyl ether 100% as mobile phase to yield the product asa colorless liquid (yield = 55 ± 5%) (Fig. 1A). Finally the product was stored under inert gas at 20 C until further use.
  • 45
  • [ 4781-83-3 ]
  • bovine serum albumin [ No CAS ]
  • bovine serum albumin modified with 2-iminothiolane [ No CAS ]
YieldReaction ConditionsOperation in experiment
With ethylenediaminetetraacetic acid; In aq. phosphate buffer; at 20℃;pH 8; Preparation of 2-Iminothiolane modified BSA: 2-Iminothiolane hydrochloride solution (0.042 ml40 mg/ml Phosphate Buffered Saline, pH 8.0 with 100 mM ethylene diamine tetraacetic acid (EDTA)) was added drop-wise to carrier protein BSA (20 mg) dissolved in Phosphate Buffered Saline, pH 8.0 with 100 mM EDTA (1 ml) while stirring. And then the resulting solution was rolled at room temperature overnight. Excess 2-Iminothiolane hydrochloride was removed by dialysis at 4 C. against PBS, pH 8.0 with 2.0 mM EDTA.
  • 46
  • keyhole limpet haemocyanin [ No CAS ]
  • [ 4781-83-3 ]
  • keyhole limpet haemocyanin modified with 2-iminothiolane [ No CAS ]
YieldReaction ConditionsOperation in experiment
With ethylenediaminetetraacetic acid; In aq. phosphate buffer; at 20℃;pH 8; 2-Iminothiolane hydrochloride solution (0.212 ml40 mg/ml Phosphate Buffered Saline, pH 8.0 with 100 mM EDTA) was added drop-wise to carrier protein KLH (100 mg) dissolved in Phosphate Buffered Saline, pH 8.0 with 100 mM EDTA (5 ml) while stirring. And then the resulting solution was rolled at room temperature overnight. Excess 2-Iminothiolane hydrochloride was removed by dialysis at 4 C. against PBS, pH 8.0 with 2.0 mM EDTA. BSA, KLH or HRP are modified with 2-iminothiolane which converts amino groups to thiols for reaction with the maleimide containing hapten A forming a thioether bond. The crosslinker X is defined as A-B-D with A=N, D=S and B equal to everything in between
  • 47
  • [ 4781-83-3 ]
  • horseradish peroxidase [ No CAS ]
  • horseradish peroxidase modified with 2-iminothiolane [ No CAS ]
YieldReaction ConditionsOperation in experiment
With ethylenediaminetetraacetic acid; In aq. phosphate buffer; at 20℃;pH 8; 2-Iminothiolane hydrochloride solution (0.05 ml 6.25 mg/ml in 50 mM Phosphate Buffered Saline, pH 8.0 with 2.0 mM EDTA) was added drop-wise to HRP (20 mg) dissolved in 50 mM Phosphate Buffered Saline, pH 8.0 with 100 mM EDTA (1.0 ml) while stirring. And then the resulting solution was rolled at room temperature overnight. Excess 2-Iminothiolane hydrochloride was removed with PD-10 column (Pharmacia), pre-equilibrated with 50 mM PBS pH 8.0 with 2.0 mM EDTA. Keep the solution in the dark during the conjugation.
  • 48
  • [ 4781-82-2 ]
  • [ 4781-83-3 ]
  • 49
  • mouse anti-GAPDH monoclonal antibody [ No CAS ]
  • C40H65N6O17P3 [ No CAS ]
  • [ 4781-83-3 ]
  • dC<SUP>mouse anti-GAPDH monoclonal antibody-EMCS</SUP>TP [ No CAS ]
YieldReaction ConditionsOperation in experiment
In aq. phosphate buffer; at 4℃; for 16h; Synthesis of primary antibody-labeled nucleotide (dC ^^TP) (0492) The antibody-labeled dNTP has been prepared by reacting of amino-modified nucleotide (dCc16NH2TP) with EMCS linker (6-maleimidohexanoic acid N-hydroxysuccinimide ester) followed by addition of sulfhydryl-functionalized antibody. The amino-modified nucleotide (dCc16NH2TP,10 eq.) was mixed with EMCS linker (6-maleimidohexanoic acid N- hydroxysuccinimide ester, 10 eq.) in PBS buffer (pH 7.2) for 2 h at room temperature. The primary antibody (mouse anti-GAPDH monoclonal antibody, 100 mug) was mixed with <strong>[4781-83-3]Traut's reagent</strong> (10 eq.) in PBS buffer (pH 8) to get sulfhydryl-functionalized primary antibody. Afterwards, excess reagent was removed using the Amicon Ultra Centrifugal Filter. The number of sulfhydryl groups per antibody was determined with Ellman's reagent. The sulfhydryl-functionalized primary antibody was added to the solution of amino-modified nucleotide with EMCS linker and was mixed for 16 h at 4C. The solution was subjected to anion exchange FPLC (HiTrap Q HP, GE Life Science) with a gradient from Buffer A (20 mM TRIS, pH 9) to Buffer B (20 mM TRIS, 1 M NaCI, pH 9). To remove the FPLC buffer, the pooled fractions were purified via Vivaspin 6 (30,000 MWCO, Sartorius) and subsequently washed with PBS buffer. The final concentration of the obtained conjugate was determined using their respective molar extinction coefficient (204 000 M"1cm"1 at 280 nm).
  • 50
  • C50H54N4O8 [ No CAS ]
  • [ 4781-83-3 ]
  • C66H82N8O8S4*4ClH [ No CAS ]
YieldReaction ConditionsOperation in experiment
In methanol; for 1h;pH 7-8; 12.39g of the compound of formula (I) prepared in step (6) was dissolved in 100mL of methanol,Continuous access to freshly prepared anhydrous HC1 steam for about 6 hours to detect the progress of the reaction with the end of the reaction,Ventilation was stopped, the pH was adjusted to neutral to weakly basic (rhoEta = 7-8),Add 5.51g <strong>[4781-83-3]Traut's reagent</strong> and deoxygenate for 1 hour.Biotech Cellulose Ester (CE) was used after the reaction was completed in a light and anaerobic conditionDialysis Trial Kits (MFFCO 500-1000OkDa, Flat Width 31mm, Length lm, SPECTRUMLABORATORIES, Inc.) were dialyzed against small molecules.
  • 51
  • C48H87N3O70S14(14-)*14Na(1+) [ No CAS ]
  • [ 4781-83-3 ]
  • C52H94N4O70S15(14-)*14Na(1+) [ No CAS ]
Reference: [1]eLife,2017,vol. 6
  • 52
  • SSEA4-MCCa [ No CAS ]
  • [ 4781-83-3 ]
  • keyhole limpet hemocyanin [ No CAS ]
  • stage-specific embryonic antigen-4 - 4-(N-maleimidomethyl)cyclohexane-1-carboxylate - keyhole limpet hemocyanin conjugate [ No CAS ]
YieldReaction ConditionsOperation in experiment
[0124] KLH is chemically modified into a modified-KLH intermediate, and then conjugate to the sugar-MCCa to afford the crude sugar-MCCa-KLH conjugated product in a low oxygen level environment. (0206) [0125] Step 1. Thiolation of KLH (0207) The buffer-exchanged KLH was purged with inert gas. After purging, <strong>[4781-83-3]2-<strong>[4781-83-3]iminothiolane hydrochloride</strong></strong> (2-IT) is added into the KLH under inert gas protection. The reaction was stirred at 18 C for 35 min. After stirring for 35 min, the reaction crude was quickly loaded onto the prepared G-15 column for column chromatography purification. The collected fractions were sampled and tested by BCA plot and Ellman plot to confirm the product. The pooled protein intermediate modified-KLH was soon sampled for Ellman assay and BCA assay to determine the SH value and protein content. PBS buffer was added into the collected modified KLH to adjust the concentration of protein to about 0.6-1.0 mg/mL. (0208) [0126] Step 2. Conjugation of Intermediate (0209) The prepared intermediate compound (sugar-MCCa) was dissolved in PBS buffer. This intermediate was sequentially transferred into the modified-KLH bottle. Add PBS buffer solution to rinse the sugar bottle, and then transfer this solution into the conjugation reaction. After mixing, the reaction crude was sampled at first half hour, and the following 1 hour, 1.5 hour, 2 hour, and 3 hour to monitor the SH value. When the SH value was lower than 200, the sugar-MCCa-KLH conjugate was stored in a freezer for next operation stage. (0210) [0127] Step 3. Purification to afford the expected sugar-MCCa-KLH conjugated products (0211) [0128] The sugar-MCCa-KLH crude was purified by filtration of TFF system filtration or centrifuge using pH 7.2 PBS for 10 times volume. The filtrate solution was collected, and sampled for HPLC analysis. The purified sugar-MCCa-KLH was temporally stored in freezers for further release tests.
  • 53
  • C70H86N4O16 [ No CAS ]
  • [ 4781-83-3 ]
  • C66H82N8O8S4*4ClH [ No CAS ]
  • 54
  • [ 23214-92-8 ]
  • [ 4781-83-3 ]
  • C31H36N2O11S*ClH [ No CAS ]
  • 55
  • [ 4781-83-3 ]
  • [ 1499-46-3 ]
  • C11H18N4O2S [ No CAS ]
YieldReaction ConditionsOperation in experiment
In aq. phosphate buffer; at 20℃; for 12h;pH 7.4; Histidine methyl ester (HME) was synthesized using as described in Rajesh et al., ?A Simple and Efficient Diastereoselective Strecker Synthesis of Optically Pure a- Arylglycines,? Tetrahedron 55(37): 11295-11308 (1999), which is hereby incorporated by reference in its entirety. The SH-HME was synthesized by reacting HME (1 mmol) with 2- <strong>[4781-83-3]iminothiolane hydrochloride</strong> (0.4 mmol, > 98%, Sigma-Aldrich) in PBS (50 mL; pH 7.4) for 12 hours at room temperature. After washing the SH-HME using deionized water, the solution was lyophilized to obtain a powder of SH-HME
Same Skeleton Products
Historical Records

Similar Product of
[ 4781-83-3 ]

Chemical Structure| 6539-14-6

A749635[ 6539-14-6 ]

2-Iminothiolane

Reason: Free-salt